## Review setup
- **Input scope** Full manuscript text
- **Assessment boundary** Scientific content, methodological soundness, and validity of conclusions as presented in the provided manuscript
- **Shared manuscript claim summary** The authors present a dynophore-based virtual screening approach applied to human DNA topoisomerase IIα, identifying flavonoid compounds as catalytic inhibitors. They validate hits through biochemical assays, NMR binding studies, and extensive molecular dynamics simulations, proposing this as a novel strategy incorporating protein dynamics into pharmacophore-based screening.
- **Visible evidence base** Full text including abstract, introduction, results, discussion, conclusions, and methods sections; figures and tables referenced but not fully visible in the provided material
- **Missing materials affecting confidence** Figures, tables, and supplementary materials referenced in the text are not provided; specific numerical data for IC50 values, STD NMR amplification factors, and MM/GBSA energy components are only partially described in text

## Reviewer
- **Overall assessment** The manuscript presents a well-structured integration of computational and experimental methods to validate a dynophore-based virtual screening approach. The concept of incorporating dynamic information into pharmacophore modeling is timely and relevant. However, several technical aspects require clarification and additional validation before the case is fully established. The experimental validation is limited to two compounds for mechanistic studies, and the connection between the initial screening model and final binding mode, while plausible, relies on a single compound's behavior. The manuscript would benefit from more rigorous statistical treatment of the screening results and clearer presentation of the relationship between the dynophore model and the experimentally observed binding.

- **Who would be interested in the results, and why** Computational chemists and medicinal chemists working on structure-based drug design, particularly those interested in incorporating protein dynamics into virtual screening workflows. Researchers in the topoisomerase inhibitor field would also find the identification of new catalytic inhibitor scaffolds relevant. The methodological framework could interest developers of pharmacophore-based screening tools.

- **Major strengths** The study combines a relatively novel computational approach (dynophores) with experimental validation including enzymatic assays, mechanism-of-action studies, and biophysical binding confirmation. The authors are transparent about limitations, such as the lack of a co-crystal structure and the potential for multiple binding orientations. The reconnection of the final MD-based binding model to the original screening pharmacophore provides a coherent narrative validating the approach.

- **Major Concerns** 
  - R1-M1: The screening hit rate and selection criteria for experimental testing are not clearly quantified
  - R1-M2: The mechanistic distinction between catalytic inhibition and other inhibition modes requires stronger evidence
  - R1-M3: The generalizability of the dynophore approach beyond this specific target is not demonstrated
  - R1-M4: The statistical significance of the computational results, particularly the MM/GBSA energies, is not established

- **Minor Comments**
  - R1-m1: The manuscript would benefit from a more detailed description of the dynophore generation parameters
  - R1-m2: The relationship between the three pharmacophore submodels and their differential performance should be clarified
  - R1-m3: The choice of 30 ns for initial MD simulations used for dynophore generation warrants justification
  - R1-m4: The authors should clarify whether the "approximately 32,000" compounds were unique or included stereoisomers

- **Technical failings that need to be addressed before the case is established** The lack of quantitative screening statistics (enrichment factors, hit rates) and the absence of error analysis for the computational free energy calculations are the most significant technical gaps. Additionally, the experimental validation of only two compounds for mechanism-of-action studies limits the strength of the conclusions about the screening approach's general utility.

- **Assessment against Nature-style criteria** 
  - Originality: The application of dynophores to virtual screening is a relatively novel contribution, though the concept of dynamic pharmacophores has been explored previously. The specific integration with experimental validation for topoisomerase IIα adds value.
  - Scientific importance: The work addresses a real need in structure-based drug design, namely incorporating protein flexibility into screening. However, the demonstration is limited to a single target and compound class.
  - Interdisciplinary readership: The work bridges computational chemistry, structural biology, and medicinal chemistry, which could appeal to a broad audience. However, the technical depth in each area may limit accessibility.
  - Technical soundness: The computational methods are generally appropriate, but the lack of statistical rigor in some analyses and the limited experimental validation of the screening predictions weaken the technical case.
  - Readability for nonspecialists: The manuscript is clearly written but assumes familiarity with pharmacophore modeling, MD simulations, and topoisomerase biology. The figures, not visible in the provided material, would be critical for accessibility.

- **Recommendation posture** Supportive if technical concerns are resolved, particularly regarding quantitative screening metrics and statistical treatment of computational results.

## Risk / unsupported claims
- The claim that the dynophore approach "validates" the screening strategy is not fully supported given that only one compound's binding mode was extensively studied
- The statement that the approach "expands the known chemical space of topoisomerase IIα inhibitors" is not quantified and cannot be assessed without the full screening results
- The assertion that the dynophore model "supplements static structure-based pharmacophore information with a dynamic component" is reasonable but the specific advantage over static methods is not demonstrated through comparative analysis
- The estimated binding free energy of -35.13 ± 3.7 kcal/mol is presented without comparison to experimental binding affinities, making the absolute value difficult to interpret
- The claim that the transducer domain flexibility "does not affect the binding of the ligand" is based on a single simulation and requires additional evidence